Bringing Bispecific Antibody Therapy to Community Oncology Centers
In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.
In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.
This phase 2 nonrandomized clinical trial assesses the efficacy and safety of dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions…
Most counties in the United States do not have active cancer clinical trials, according to results of an ASCO analysis.More than half of the country’s…
In this issue of Blood Advances, Pophali et al1 demonstrate the efficacy and safety of CD19-directed chimeric antigen receptor (CAR) T-cell therapy in pati
Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.
According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.
The AACR and JCA are proud to offer this 13th AACR-JCA Joint Conference which brings together outstanding researchers from the U.S., Japan, and around the…
Blood | 144 | 17 | October 2024
Radiation therapy (RT) is a critical treatment modality for both primary and metastatic brain tumors, yet approximately 30% of patients experience cognitive decline post-radiotherapy. This…